Institut Català de la Salut
[Pieren DKJ, Kuguel SG, Robles AG, Rey-Cano J, Mancebo C, Falcó V, Buzón MJ, Genescà M] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rosado J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cirurgia Toràcica i Trasplantament Pulmonar, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Esperalba J] Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-04-26T09:21:21Z
2023-04-26T09:21:21Z
2023-04-05
SARS-CoV-2; T cells; Vaccines
SARS-CoV-2; Células T; Vacunas
SARS-CoV-2; Cèl·lules T; Vacunes
Resident memory T cells (TRM) present at the respiratory tract may be essential to enhance early SARS-CoV-2 viral clearance, thus limiting viral infection and disease. While long-term antigen-specific TRM are detectable beyond 11 months in the lung of convalescent COVID-19 patients, it is unknown if mRNA vaccination encoding for the SARS-CoV-2 S-protein can induce this frontline protection. Here we show that the frequency of CD4+ T cells secreting IFNγ in response to S-peptides is variable but overall similar in the lung of mRNA-vaccinated patients compared to convalescent-infected patients. However, in vaccinated patients, lung responses present less frequently a TRM phenotype compared to convalescent infected individuals and polyfunctional CD107a+ IFNγ+ TRM are virtually absent in vaccinated patients. These data indicate that mRNA vaccination induces specific T cell responses to SARS-CoV-2 in the lung parenchyma, although to a limited extend. It remains to be determined whether these vaccine-induced responses contribute to overall COVID-19 control.
This work was supported by grants from Fundació La Marató TV3 (201814-10 FMTV3 and 202112-30 FMTV3, M.G.), from the Health department of the Government of Catalonia (DGRIS 1_5, to M.G. and M.J.B). M.J.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179).
Article
Published version
English
COVID-19 (Malaltia) - Vacunació; Cèl·lules T; Immunoglobulines; ANATOMY::Hemic and Immune Systems::Blood::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Hemic and Immune Systems::T-Lymphocytes; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Viral; PHENOMENA AND PROCESSES::Immune System Phenomena::Immunity::Adaptive Immunity::Immunologic Memory; ANATOMÍA::sistemas sanguíneo e inmunológico::sangre::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::sistemas sanguíneo e inmunológico::linfocitos T; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricos; FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunidad::inmunidad adaptativa::memoria inmunológica
Springer Nature
Nature Communications;14
https://doi.org/10.1038/s41467-023-37559-w
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1665]